Zhitong Finance App News, Hengrui Pharmaceutical (01276) issued an announcement. Recently, Guangdong Hengrui Pharmaceutical Co., Ltd., a subsidiary of Jiangsu Hengrui Pharmaceutical Co., Ltd. (hereinafter referred to as the “Company”), received approval from the State Drug Administration (hereinafter referred to as the “State Drug Administration”) to issue a “Drug Clinical Trial Approval Notice” for SHR-1139 injections and will conduct clinical trials in the near future.

SHR-1139 injection is a bispecific antibody independently developed by the company that targets IL-23p19 and IL-36R at the same time, blocks both pathways, and may provide more comprehensive and long-lasting inflammation control. According to inquiries, there are currently no similar drugs approved for marketing at home or abroad. Up to now, the total R&D investment for SHR-1139 injection-related projects is about 162.7 million yuan (unaudited).

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.